



(51) International Patent Classification:

A61K 31/4439 (2006.01) A61K 39/395 (2006.01)
A61K 31/12 (2006.01) A61P 35/00 (2006.01)
A61K 31/20 (2006.01) C12Q 1/68 (2006.01)
A61K 31/7088 (2006.01) G01N 33/574 (2006.01)

(21) International Application Number:

PCT/CA2013/050821

(22) International Filing Date:

30 October 2013 (30.10.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/720,218 30 October 2012 (30.10.2012) US
61/870,418 27 August 2013 (27.08.2013) US
61/870,435 27 August 2013 (27.08.2013) US

(71) Applicant: PACYLEX PHARMACEUTICALS INC.
[CA/CA]; 2600 Manulife Place, 10180-101 Street, Edmon-
ton, Alberta T5J 3Y2 (CA).(72) Inventors: BERTHIAUME, Luc, G.; 10061 90 Avenue,
Edmonton, Alberta T6E 4X2 (CA). PERINPANAY-
AGAM, Conganige, Maneka, Anne; Unit 8, 2004,
Grantham Court NW, Edmonton, Alberta T5T 6R9 (CA).
YAP, Chuiyee; 4836 155 Avenue, Edmonton, Alberta

T5Y 0C1 (CA). BEAUCHAMP, Erwan; 13 rue Renée
Prévert, F-35000 Rennes (FR).

(74) Agents: VICKERS, Mark, F. et al.; Borden Ladner Ger-
vais LLP, World Exchange Plaza, 100 Queen Street, Suite
1300, Ottawa, Ontario K1P 1J9 (CA).


(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: SYNTHETIC LETHALITY AND THE TREATMENT OF CANCER

Figure 8



NMT-1 stain. Upper row: N1, N2 normal lymph nodes,
Neg Negative control. Middle row: three Burkitt
lymphoma cases (BL 1-3). Lower row: three DLBCL
(LCL-1-3) cases. Both normal lymph nodes and
lymphoma show strong stains. No difference
observed.

(57) Abstract: Described herein are compounds, composi-
tions and methods for treatment of cancer. Also described are
methods and uses for identifying subject with cancer that are
suitable for treatment with the compounds, composition and
methods are described herein. In one aspect of the present in-
vention, there is provided a method of treating a subject hav-
ing a cancer deficient in NMT2, comprising: administering to
said subject an NMT inhibitor.

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*